CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: Final analysis of a prospective phase II trial

Annals of Hematology

Volumn 92, Issue 11, 2013, Pages 1521-1528

  Binder, C ^a   Ziepert, M ^b   Pfreundschuh, M ^c   Duhrsen U ^e   Eimermacher, H ^f   Aldaoud, A ^g   Rosenwald, A ^h   Loeffler, M ^b   Schmitz, N ^d   Truemper, L ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f Catholic Hospital   (Germany)

^g Oncologic Outpatient Clinics   (Germany)

^h UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Alemtuzumab; Phase II trial; T cell lymphoma

Indexed keywords

ALEMTUZUMAB; CLEMASTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PARACETAMOL; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGRESSION; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GRAM NEGATIVE SEPSIS; HERPES ZOSTER; HUMAN; INDUCTION CHEMOTHERAPY; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LIVER FAILURE; LUNG MYCOSIS; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; REVIEW; SALVAGE THERAPY; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DRUG ADMINISTRATION; FOLLOW UP; LYMPHOMA, T-CELL, PERIPHERAL; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84885594347     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1880-4     Document Type: Review

References (30)

1. Foss FM, Zinzani PL, Vose JM et al (2011) Peripheral T-cell lymphoma. Blood 117:6756-6767
2. Weisenburger DD, Savage KJ, Harris NL et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402-3408
3. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130
4. Akagi T, Takahashi N, Yamaguchi K et al (2011) Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum. J Clin Exp Hematop 51:29-35
5. Gisselbrecht C, Gaulard P, Lepage E et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92:76-82
6. The International Non-Hodgkin's Lymphoma Prognostic Factors Project, Shipp MA, Harrington DP et al (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
7. Savage KJ (2011) Update: peripheral T-cell lymphomas. Curr Hematol Malig Rep 6:222-230
8. Schmitz N, Trumper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418-3425
9. Corradini P, Tarella C, Zallio F et al (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533-1538
10. Gisselbrecht C, Lepage E, Molina T et al (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479
11. Nickelsen M, Ziepert M, Zeynalova S et al (2009) High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20:1977-1984
12. Mounier N, Gisselbrecht C, Briere J et al (2004) All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 15:1790-1797
13. Kyriakou C, Canals C, Goldstone A et al (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:218-224
14. Rodriguez J, Conde E, Gutierrez A et al (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79:32-38
15. Reimer P, Rudiger T, Geissinger E et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27:106-113
16. D'Amore F, Relander T, Lauritzsen GF et al (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30:3093-9
17. Ginaldi L, De MM, Matutes E et al (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22:185-191
18. Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica 92:566-567
19. Dearden CE (2006) T-cell prolymphocytic leukemia. Med Oncol 23:17-22
20. Lundin J, Hagberg H, Repp R et al (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101:4267-4272
21. Enblad G, Hagberg H, Erlanson M et al (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920-2924
22. Kim SJ, Kim K, Park Y et al (2012) Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest New Drugs 30:368-375
23. Zinzani PL, Alinari L, Tani M et al (2005) Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90:702-703
24. Cheson B, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253
25. Wunderlich A, Kloess M, Reiser M et al (2003) Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 14:881-893
26. Gallamini A, Zaja F, Patti C et al (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323
27. Kim JG, Sohn SK, Chae YS et al (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 60:129-134
28. Weidmann E, Hess G, Chow KU et al (2010) A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma 51:447-455
29. Kluin-Nelemans HC, van Marwijk KM, Lugtenburg PJ et al (2011) Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 22:1595-1600
30. Simon A, Peoch M, Casassus P et al (2010) Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Brit J Haematol 151:159-166